Nasdaq · Biotech stocks database
SNY (Sanofi) stock: $42.12, $102.71B market cap, $9.00B cash, $93.72B EV, $101.43B fully diluted market cap. Next expected readout: Sep-26. Lead program: Itepekimab (SAR440340) (Chronic Rhinosinusitis With Nasal Polyps), Phase 3. Data from Fully Diluted's biotech stocks database.
| Cash | $8,997.0M |
|---|---|
| Debt | $0.0M |
| Net cash | $8,997.0M |
| Enterprise value | $93,715.3M |
| Basic shares | 1,219.4M shares |
| Fully diluted shares | 2,408.1M shares |
| Fully diluted market cap | $101,430.4M |
| Cash per share | $7.38 |
Cash figures as of 2025-12-31. Database snapshot: 2026-09-22.
Loading SNY daily closes…
| Expected | Drug | Phase | Indication | Mgmt guide |
|---|---|---|---|---|
| Now - Oct 22, 2026 | SAR441566 | Phase 2 | Crohn's Disease | — |
| Now - Oct 24, 2026 | Aficamten | Phase 3 | Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy | — |
| Now - Oct 28, 2026 | Amlitelimab | Phase 2 | Coeliac Disease; Celiac Disease | — |
| Now - Oct 29, 2026 | SAR441566 | Phase 2 | Colitis Ulcerative | — |
| Oct 6 - Nov 17 | Rilzabrutinib dose 1 | Phase 2 | Graves' Disease | — |
| Oct 15 - Nov 26 | SAR441344 IV | Phase 2 | Systemic Lupus Erythematosus | — |
| Nov 9 - Dec 21 | Belumosudil | Phase 1 | Chronic Graft Versus Host Disease | — |
| Nov 10 - Dec 22 | Amlitelimab | Phase 2 | Asthma | — |
| Nov 11 - Dec 23 | balinatunfib | Phase 2 | Colitis Ulcerative; Crohn's Disease | — |
| Nov 11 - Dec 23 | Dupilumab coformulated with berahyaluronidase alfa | Phase 1 | Healthy Volunteers | — |
| Nov 18 - Dec 30 | Dupilumab | Phase 3 | Atopic Dermatitis | — |
| Nov 25, 2026 - Jan 6, 2027 | Itepekimab (SAR440340) | Phase 3 | Chronic Rhinosinusitis With Nasal Polyps | — |
| Dec 11, 2026 - Jan 22, 2027 | venglustat (GZ402671) | Phase 2 | Gaucher Disease Type 1; Gaucher Disease Type 3 | — |
| Dec 13, 2026 - Jan 24, 2027 | Amlitelimab | Phase 2 | Interstitial Lung Disease Due to Systemic Disease; Scleroderma | — |
| Dec 17, 2026 - Jan 28, 2027 | Fitusiran | Phase 3 | Hemophilia | — |
| Dec 18, 2026 - Jan 29, 2027 | Itepekimab (SAR440340) | Phase 3 | Chronic Rhinosinusitis With Nasal Polyps | — |
| Jan 11 - Feb 22 | rilzabrutinib | Phase 3 | Immune Thrombocytopenia | — |
| Jan 12 - Feb 23 | Itepekimab (SAR440340) | Phase 3 | Chronic Obstructive Pulmonary Disease | — |
| Jan 12 - Feb 23 | PCV21 | Phase 3 | Pneumococcal Infections | — |
| Jan 28 - Mar 11 | SAR442970 | Phase 2 | Crohn's Disease | — |
| Jan 28 - Mar 11 | SAR442970 | Phase 2 | Ulcerative Colitis | — |
| Feb 3 - Mar 17 | frexalimab | Phase 2 | Focal Segmental Glomerulosclerosis; Glomerulonephritis Minimal Lesion | — |
| Feb 11 - Mar 25 | Belumosudil | Phase 2 | Chronic Graft Versus Host Disease | — |
| Feb 18 - Apr 1 | PCV21 | Phase 3 | Sickle Cell Disease | — |
| Feb 19 - Apr 2 | Isatuximab SC-OBDS | Phase 2 | Plasma Cell Myeloma Refractory | — |
| Feb 26 - Apr 9 | efanesoctocog alfa (BIVV001) | Phase 3 | Hemophilia A | — |
| Mar 2 - Apr 13 | SAR445877 | Phase 2 | Solid Tumor | — |
| Mar 23 - May 4 | Brivekimig | Phase 2 | Hidradenitis Suppurativa | — |
| Mar 31 - May 12 | Itepekimab (SAR440340) | Phase 3 | Chronic Rhinosinusitis With Nasal Polyps | — |
| May 6 - Jun 17 | Fitusiran | Phase 3 | Hemophilia | — |
| May 16 - Jun 27 | H5 Flu Investigational Medical Product (IMP) 1 | Phase 1 | Respiratory Syncytial Virus (RSV); Influenza A(H5N1) | — |
| May 17 - Jun 28 | Isatuximab SAR650984 | Phase 3 | Plasma Cell Myeloma | — |
| May 20 - Jul 1 | SAR444336 | Phase 2 | Microscopic Colitis | — |
| Jun 9 - Jul 21 | Frexalimab | Phase 2 | Type 1 Diabetes Mellitus | — |
| Jun 10 - Jul 22 | Brivekimig | Phase 2 | Type 1 Diabetes Mellitus | — |
| Jun 17 - Jul 29 | Frexalimab | Phase 3 | Multiple Sclerosis | — |
| Jun 29 - Aug 10 | SAR402663 | Phase 2 | Neovascular Age-related Macular Degeneration | — |
| Jul 14 - Aug 25 | Dupilumab | Phase 3 | Pruritus | — |
| Aug 2 - Sep 13 | Lunsekimig | Phase 2 | Asthma | — |
| Aug 20 - Oct 1 | riliprubart | Phase 3 | Chronic Inflammatory Demyelinating Polyneuropathy | — |
| Aug 26 - Oct 7 | Frexalimab | Phase 3 | Multiple Sclerosis | — |
| Sep 3 - Oct 15 | Rilzabrutinib | Phase 3 | Sickle Cell Disease | — |
| Oct 25 - Dec 6 | Isatuximab | Phase 2 | Plasma Cell Myeloma Refractory | — |
| Nov 3 - Dec 15 | SAR445399 | Phase 2 | Hidradenitis Suppurativa | — |
| Nov 11 - Dec 23 | Amlitelimab | Phase 3 | Dermatitis Atopic | — |
| Nov 24, 2027 - Jan 5, 2028 | SAR446597 | Phase 2 | Geographic Atrophy | — |
| Dec 9, 2027 - Jan 20, 2028 | Dupilumab | Phase 3 | Prurigo Nodularis | — |
| Dec 17, 2027 - Jan 28, 2028 | rilzabrutinib | Phase 3 | Immune Thrombocytopenia | — |
| Jan 12 - Feb 23 | Lenalidomide | Phase 2 | Newly Diagnosed Multiple Myeloma | — |
| Mar 3 - Apr 14 | SAR448501 | Phase 1 | B-cell Non Hodgkin Lymphoma | — |
| Mar 29 - May 10 | SAR447971 | Phase 1 | Hidradenitis; Healthy Volunteers | — |
| Apr 12 - May 24 | Sarilumab SAR153191 (REGN88) | Phase 2 | Juvenile Idiopathic Arthritis | — |
| Apr 17 - May 29 | Teplizumab | Phase 2 | Type 1 Diabetes Mellitus | — |
| May 5 - Jun 16 | Frexalimab | Phase 3 | Multiple Sclerosis | — |
| Jun 14 - Jul 26 | RSV | Phase 2 | Respiratory Syncytial Virus Immunization; Human Metapneumovirus Immunization; Healthy Volunteers | — |
| Jun 20 - Aug 1 | Duvakitug | Phase 3 | Ulcerative Colitis | — |
| Jul 12 - Aug 23 | rilzabrutinib | Phase 3 | Autoimmune Haemolytic Anaemia | — |
| Jul 18 - Aug 29 | Teplizumab | Phase 3 | Type 1 Diabetes Mellitus | — |
| Jul 28 - Sep 8 | Duvakitug | Phase 2 | Hidradenitis | — |
| Jul 31 - Sep 11 | dupilumab | Phase 3 | Eosinophilic Esophagitis (EoE) | — |
| Aug 9 - Sep 20 | Rilzabrutinib | Phase 3 | Immunoglobulin G4 Related Disease | — |
| Aug 11 - Sep 22 | SAR447537 | Phase 2 | Alpha 1-Antitrypsin Deficiency; Emphysema | — |
| Aug 14 - Sep 25 | Bivalent RSV | Phase 2 | Respiratory Syncytial Virus; Human Metapneumovirus; Healthy Volunteers | — |
| Sep 13 - Oct 25 | SAR445877 | Phase 2 | Gastric Cancer; Oesophageal Carcinoma | — |
| Nov 2 - Dec 14 | Duvakitug | Phase 3 | Ulcerative Colitis | — |
| Nov 6 - Dec 18 | Belumosudil | Phase 2 | Chronic Graft Versus Host Disease | — |
| Nov 10 - Dec 22 | Belumosudil | Phase 3 | Chronic Graft Versus Host Disease | — |
| Dec 7, 2028 - Jan 18, 2029 | Sarilumab, SAR153191 SC | Phase 2 | Rheumatoid Arthritis | — |
| Jan 11 - Feb 22 | Isatuximab intravenous (IV) | Phase 2 | Plasma Cell Myeloma | — |
| Feb 1 - Mar 15 | Dupilumab | Phase 3 | Wheezing; Asthma | — |
| Mar 5 - Apr 16 | Amlitelimab | Phase 3 | Dermatitis Atopic | — |
| Mar 12 - Apr 23 | Belumosudil | Phase 3 | Lung Transplant Rejection | — |
| Apr 11 - May 23 | SAR446268 | Phase 2 | Myotonic Dystrophy | — |
| Jun 11 - Jul 23 | Tolebrutinib | Phase 3 | Relapsing Multiple Sclerosis; Secondary Progressive Multiple Sclerosis; Progressive Relapsing Multiple Sclerosis | — |
| Jun 25 - Aug 6 | Duvakitug | Phase 3 | Crohn's Disease | — |
| Aug 6 - Sep 17 | SAR448501 | Phase 1 | Systemic Lupus Erythematosus (SLE); Rheumatoid Arthritis (RA) | — |
| Sep 11 - Oct 23 | SAR448851 | Phase 2 | Dementia, Alzheimer's Type; Alzheimer's Disease | — |
| Sep 15 - Oct 27 | Fitusiran | Phase 3 | Hemophilia | — |
| Sep 24 - Nov 5 | Duvakitug | Phase 3 | Crohn's Disease | — |
| Sep 26 - Nov 7 | Frexalimab | Phase 3 | Kidney Transplant Rejection | — |
| Oct 13 - Nov 24 | BLU-924 | Phase 2 | Advanced Solid Tumor; Non-Small Cell Lung Cancer; Colorectal Neoplasms | — |
| Oct 24 - Dec 5 | PF-08046050 | Phase 1 | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Stomach Neoplasms | — |
| Oct 26 - Dec 7 | Belumosudil | Phase 3 | Chronic Graft Versus Host Disease | — |
| Nov 14 - Dec 26 | Riliprubart Prefilled Pen (PFP) | Phase 3 | Polyneuropathy, Inflammatory Demyelinating, Chronic | — |
| Jan 8 - Feb 19 | Lunsekimig | Phase 3 | Chronic Obstructive Pulmonary Disease | — |
| Jan 8 - Feb 19 | Lunsekimig | Phase 3 | Chronic Obstructive Pulmonary Disease | — |
| May 14 - Jun 25 | SAR444836 | Phase 2 | Phenylketonuria | — |
| Nov 25, 2030 - Jan 6, 2031 | Isatuximab SAR650984 | Phase 3 | Plasma Cell Myeloma | — |
| Mar 3 - Apr 14 | Lunsekimig | Phase 2 | Asthma | — |
| Mar 12 - Apr 23 | Lunsekimig | Phase 2 | Chronic Rhinosinusitis With Nasal Polyps | — |
| Jun 27 - Aug 8 | SAR446523 | Phase 1 | Plasma Cell Myeloma Refractory | — |
| Jul 23 - Sep 3 | Amlitelimab | Phase 2 | Dermatitis Atopic | — |
| Jul 25 - Sep 5 | Blood draw for the laboratory assessment | Phase 2 | Usher's Syndrome | — |
| Sep 3 - Oct 15 | Lunsekimig | Phase 3 | Chronic Obstructive Pulmonary Disease | — |
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.